UK medical eligibility criteria for contraceptive use (UKMEC) guideline

Faculty of Sexual & Reproductive Healthcare


Share on Google+
|
| Earn 0.5 Credits

  • This Guidelines summary covers the key conditions that women commonly present with in a primary care setting. Please refer to the full guideline for evidence, clarifications, and additional comments associated with the recommendations

Aims of the UKMEC guideline

Using the UKMEC tables

Initiation and continuation of a method

Drug interactions with hormonal contraception

Personal characteristics and reproductive history

Cardiovascular disease

Neurological conditions

Depressive disorders

Reproductive tract conditions

Breast conditions

Infection

Endocrine conditions

Gastrointestinal conditions

Anaemias

Rheumatic diseases

Drug interactions

Aims of the UKMEC guideline

  • The UK medical eligibility criteria for contraceptive use (UKMEC) offers evidence-based recommendations on the possible contraceptive methods that could be used safely by individuals with certain health conditions or characteristics to prevent an unintended pregnancy
  • The guidance does not indicate a best method for a woman nor do they take into account efficacy (and this includes drug interactions or malabsorption)

Using the UKMEC tables

Condition

  • The first column indicates the condition. Each condition is defined as representing either an individual’s characteristics (e.g. age, parity) or a known pre-existing medical condition (e.g. diabetes, hypertension). Some conditions are subdivided to differentiate between varying degrees of the condition (e.g. migraine with or without aura)

Methods of contraception

  • The tables in this Guidelines summary considers the following methods of contraception:
    • copper-bearing intrauterine device
    • levonorgestrel-releasing intrauterine system
    • progestogen-only:
      • implant
      • injectable
      • pill
    • combined hormonal contraception
  • Please refer to the full guideline for the UKMEC table for emergency contraception
  • Please note that the contraceptive methods are now reordered (from left to right) in the tables to broadly reflect long-acting/more effective to shorter acting/less effective methods. This is a key change from the previous edition of the UKMEC guidance

The UKMEC categories

  • The category (UKMEC 1 to 4) for each condition is given for each method of contraception. Occasionally, NA (not applicable) is used, which denotes a condition for when a ranking was not given but clarifications have been provided in the full guideline
  • The definitions of the categories are given in the tables in this Guidelines summary
  • If a contraception is used for a non-contraceptive indication (e.g. management of heavy menstrual bleeding) the risk/benefit profile and eligibility criteria may differ
  • Categories cannot be added together to indicate the safety of using a method. For example, if a woman has two conditions that are each UKMEC 2 for use of CHC, these should not be added to make a UKMEC 4. However, if multiple UKMEC 2 conditions are present that all relate to the same risk, clinical judgement must be used to decide whether the risks of using the method may outweigh the benefits. For example, consider a 34-year-old woman wishing to use combined hormonal contraception (CHC) who has a body mass index (BMI) of 34 kg/m2 (UKMEC 2), is a current smoker (UKMEC 2), has a history of superficial venous thrombosis (UKMEC 2), and has a first-degree relative who had a venous thromboembolic event at age 50 years (UKMEC 2), all potential risk factors for venous thromboembolism (VTE). She might be better advised to consider a different method of contraception that does not increase her risk of VTE
  • When an individual has multiple conditions all scoring UKMEC 3 for a method, use of this method may pose an unacceptable risk; clinical judgement should be used in each individual case

Initiation and continuation of a method

  • The initiation (I) and continuation (C) of a method of contraception can sometimes be distinguished and classified differently (see tables in this Guidelines summary). The duration of use of a method of contraception prior to the new onset of a medical condition may influence decisions regarding continued use. However, there is no set duration and clinical judgement will be required

Drug interactions with hormonal contraception

  • Drug interactions can potentially cause adverse effects. Health professionals providing hormonal contraception should ask women about their current and previous drug use including prescription, over-the-counter, herbal, recreational drugs, and dietary supplements. Women should be advised to use the most effective methods for them; this may include the additional use of non-hormonal barrier methods when potential drug interactions pose concern
  • For further information on drug interactions, please refer to:

Personal characteristics and reproductive history

CONDITION Cu-IUD LNG-IUS IMP DMPA POP CHC
PERSONAL CHARACTERISTICS AND REPRODUCTIVE HISTORY
Pregnancy NA NA NA NA NA NA
Age Menarche to <20=2,≥20=1 Menarche to <20=2, ≥20=1 After menarche=1 Menarche to <18=2, 18-45=1, >45=2
After menarche=1 Menarche to <40=1, ≥40=2
Parity
(a) Nulliparous 1 1 1 1 1 1
(b) Parous 1 1 1 1 1 1
Breastfeeding
(a) 0 to <6 weeks postpartum See below 1 2 1 4
(b) ≥6 weeks to <6 months (primarily breastfeeding) 1 1 1 2
(c) ≥6 months postpartum 1 1 1 1
Postpartum (in non-breastfeeding women)
(a) 0 to <3 weeks
(i) With other risk factors for VTE See below 1 2 1 4
(ii) Without other risk factors 1 2 1 3
(b) 3 to <6 weeks
(i) With other risk factors for VTE See below 1 2 1 3
(ii) Without other risk factors 1 1 1 2
(c) ≥6 weeks 1 1 1 1
Postpartum (in breastfeeding or non-breastfeeding women, including post caesarean section)
(a) 0 to <48 hours 1 1 See above
(b) 48 hours to <4weeks 3 3
(c) ≥4 weeks 1 1
(d) Postpartum sepsis 4 4
Cu-IUD=copper-bearing intrauterine device; LNG-IUS=levonorgestrel-releasing intrauterine system; IMP=progestogen-only implant; DMPA=progestogen-only injectable; POP=progestogen-only pill; CHC=combined hormonal contraception; NA=not applicable; VTE=venous thromboembolism.

UKMEC DEFINITION OF CATEGORY
Category 1 A condition for which there is no restriction for the use of the method
Category 2
A condition where the advantages of using the method generally outweigh the theoretical or proven risks
Category 3
A condition where the theoretical or proven risks usually outweigh the advantages of using the method. The provision of a method requires expert clinical judgement and/or referral to a specialist contraceptive provider, since use of the method is not usually recommended unless other more appropriate methods are not available or not acceptable
Category 4
A condition which represents an unacceptable health risk if the method is used

CONDITION Cu-IUD LNG-IUS IMP DMPA POP CHC
PERSONAL CHARACTERISTICS AND REPRODUCTIVE HISTORY (CONTINUED)
Post-abortion
(a) First trimester 1 1 1 1 1 1
(b) Second trimester 2
2
1 1 1 1
(c) Post-abortion sepsis 4 4 1 1 1 1
Past ectopic pregnancy 1 1 1 1 1 1
History of pelvic surgery (including caesarean section) 1 1 1 1 1 1
Smoking
(a) Age <35 years 1 1 1 1 1 2
(b) Age ≥35 years
(i) <15 cigarettes/day 1 1 1 1 1 3
(ii) ≥15 cigarettes/day 1 1 1 1 1 4
(iii) Stopped smoking <1 year 1 1 1 1 1 3
(iv) Stopped smoking ≥1 year 1 1 1 1 1 2
Obesity
(a) BMI ≥30–34 kg/m2 1 1 1 1 1 2
(b) BMI ≥35 kg/m2 1 1 1 1 1 3
History of bariatric surgery
a) With BMI <30 kg/m2 1 1 1 1 1 1
b) With BMI ≥30–34 kg/m2 1 1 1 1 1 2
c) With BMI ≥35 kg/m2 1 1 1 1 1 3
Please refer to the full guideline for recommendations on organ transplant
Cu-IUD=copper-bearing intrauterine device; LNG-IUS=levonorgestrel-releasing intrauterine system; IMP=progestogen-only implant; DMPA=progestogen-only injectable; POP=progestogen-only pill; CHC=combined hormonal contraception; BMI=body mass index.
UKMEC DEFINITION OF CATEGORY
Category 1 A condition for which there is no restriction for the use of the method
Category 2
A condition where the advantages of using the method generally outweigh the theoretical or proven risks
Category 3
A condition where the theoretical or proven risks usually outweigh the advantages of using the method. The provision of a method requires expert clinical judgement and/or referral to a specialist contraceptive provider, since use of the method is not usually recommended unless other more appropriate methods are not available or not acceptable
Category 4
A condition which represents an unacceptable health risk if the method is used

Cardiovascular disease

CONDITION Cu-IUD LNG-IUS IMP DMPA POP CHC
CARDIOVASCULAR DISEASE
Multiple risk factors for CVD (such as smoking, diabetes, hypertension, obesity and dyslipidaemias) 1 2
2
3
2
3
Hypertension
(a) Adequately controlled hypertension 1 1
1 2
1 3
(b) Consistently elevated BP levels (properly taken measurements)
(i) Systolic >140–159 mmHg or diastolic >90–99 mmHg 1 1 1 1 1 3
(ii) Systolic ≥160 mmHg or diastolic ≥ 100 mmHg 1 1 1 2 1 4
(c) Vascular disease 1 2 2
3
2
4
History of high BP during pregnancy 1 1 1 1 1 2
Current and history of ischaemic heart disease 1 I C I C 3 I C 4
2 3 2 3 2 3
Stroke (history of cerebrovascular accident, including TIA) 1 I C I
C 3 I C 4
2 3 2 3 2 3
Known dyslipidaemias 1 2 2 2 2 2
I=initiation: starting a method by a woman with a specific medical condition. C=continuation: continuing with the method already being used by a woman who develops a new medical condition. Cu-IUD=copper-bearing intrauterine device; LNG-IUS=levonorgestrel-releasing intrauterine system; IMP=progestogen-only implant; DMPA=progestogen-only injectable; POP=progestogen-only pill; CHC=combined hormonal contraception; CVD=cardiovascular disease; BP=blood pressure; TIA=transient ischaemic attack.

UKMEC DEFINITION OF CATEGORY
Category 1 A condition for which there is no restriction for the use of the method
Category 2
A condition where the advantages of using the method generally outweigh the theoretical or proven risks
Category 3
A condition where the theoretical or proven risks usually outweigh the advantages of using the method. The provision of a method requires expert clinical judgement and/or referral to a specialist contraceptive provider, since use of the method is not usually recommended unless other more appropriate methods are not available or not acceptable
Category 4
A condition which represents an unacceptable health risk if the method is used

CONDITION Cu-IUD LNG-IUS IMP DMPA POP CHC
CARDIOVASCULAR DISEASE (CONTINUED)
Venous thromboembolism
(a) History of VTE 1 2 2 2 2 4
(b) Current VTE (on anticoagulants) 1 2 2 2 2 4
(c) Family history of VTE
(i) First-degree relative age <45 years 1 1 1 1 1 3
(ii) First-degree relative age ≥45 years 1 1 1 1 1 2
(d) Major surgery
(i) With prolonged immobilisation 1 2 2 2 2 4
(ii) Without prolonged immobilisation 1 1 1 1 1 2
(e) Minor surgery without immobilisation 1 1 1 1 1 1
(f) Immobility (unrelated to surgery) (e.g. wheelchair use, debilitating illness) 1 1 1 1 1 3
Superficial venous thrombosis
(a) Varicose veins 1 1 1 1 1 1
(b) Superficial venous thrombosis 1 1 1 1 1 2
Known thrombogenic mutations (e.g. factor V Leiden, prothrombin mutation, protein S, protein C and antithrombin deficiencies) 1 2 2 2 2 4
Cu-IUD=copper-bearing intrauterine device; LNG-IUS=levonorgestrel-releasing intrauterine system; IMP=progestogen-only implant; CHC=combined hormonal contraception; VTE=venous thromboembolism. DMPA=progestogen-only injectable; POP=progestogen-only pill;

UKMEC DEFINITION OF CATEGORY
Category 1 A condition for which there is no restriction for the use of the method
Category 2
A condition where the advantages of using the method generally outweigh the theoretical or proven risks
Category 3
A condition where the theoretical or proven risks usually outweigh the advantages of using the method. The provision of a method requires expert clinical judgement and/or referral to a specialist contraceptive provider, since use of the method is not usually recommended unless other more appropriate methods are not available or not acceptable
Category 4
A condition which represents an unacceptable health risk if the method is used

CONDITION Cu-IUD LNG-IUS IMP DMPA POP CHC
CARDIOVASCULAR DISEASE (CONTINUED)
Valvular and congenital heart disease
(a) Uncomplicated 1 1 1 1 1 2
(b) Complicated (e.g. pulmonary hypertension, history of subacute bacterial endocarditis) 2 2 1 1 1 4
Cardiomyopathy
(a) Normal cardiac function 1 1 1 1 1 2
(b) Impaired cardiac function 2 2 2 2 2 4
Cardiac arrhythmias
(a) Atrial fibrillation 1 2 2 2 2 4
(b) Known long QT syndrome I C I C 1 2 1 2
3 1 3 1
I=initiation: starting a method by a woman with a specific medical condition. C=continuation: continuing with the method already being used by a woman who develops a new medical condition. Cu-IUD=copper-bearing intrauterine device; LNG-IUS=levonorgestrel-releasing intrauterine system; IMP=progestogen-only implant; DMPA=progestogen-only injectable; POP=progestogen-only pill; CHC=combined hormonal contraception.

UKMEC DEFINITION OF CATEGORY
Category 1 A condition for which there is no restriction for the use of the method
Category 2
A condition where the advantages of using the method generally outweigh the theoretical or proven risks
Category 3
A condition where the theoretical or proven risks usually outweigh the advantages of using the method. The provision of a method requires expert clinical judgement and/or referral to a specialist contraceptive provider, since use of the method is not usually recommended unless other more appropriate methods are not available or not acceptable
Category 4
A condition which represents an unacceptable health risk if the method is used

Neurological conditions

CONDITION Cu-IUD LNG-IUS IMP DMPA POP CHC
NEUROLOGICAL CONDITIONS
Headaches
(a) Non-migrainous (mild or severe) 1 1 1 1 1 I C
1 2
(b) Migraine without aura, at any age 1 2 2 2 I C I C
1 2 2 3
(c) Migraine with aura, at any age 1 2 2 2 2 4
(d) History (≥5 years ago) of migraine with aura, any age 1 2 2 2 2 3
Idiopathic intracranial hypertension 1 1 1 1 1 2
Epilepsy 1 1
1 1 1 1
Taking anti-epileptic drugs Certain anti-epileptic drugs have the potential to affect the bioavailability of steroid hormones in hormonal contraception. For up-to-date information on the potential drug interactions between hormonal contraception and anti-epileptic drugs, please refer to the online drug interaction checker available on the Medscape website (reference.medscape.com/drug-interactionchecker interaction checker)
I=initiation: starting a method by a woman with a specific medical condition. C=continuation: continuing with the method already being used by a woman who develops a new medical condition. Cu-IUD=copper-bearing intrauterine device; LNG-IUS=levonorgestrel-releasing intrauterine system; IMP=progestogen-only implant; DMPA=progestogen-only injectable; POP=progestogen-only pill; CHC=combined hormonal contraception.

UKMEC DEFINITION OF CATEGORY
Category 1 A condition for which there is no restriction for the use of the method
Category 2
A condition where the advantages of using the method generally outweigh the theoretical or proven risks
Category 3
A condition where the theoretical or proven risks usually outweigh the advantages of using the method. The provision of a method requires expert clinical judgement and/or referral to a specialist contraceptive provider, since use of the method is not usually recommended unless other more appropriate methods are not available or not acceptable
Category 4
A condition which represents an unacceptable health risk if the method is used

Depressive disorders

CONDITION Cu-IUD LNG-IUS IMP DMPA POP CHC
DEPRESSIVE DISORDERS
Depressive disorders 1 1 1 1 1 1

UKMEC DEFINITION OF CATEGORY
Category 1 A condition for which there is no restriction for the use of the method
Category 2
A condition where the advantages of using the method generally outweigh the theoretical or proven risks
Category 3
A condition where the theoretical or proven risks usually outweigh the advantages of using the method. The provision of a method requires expert clinical judgement and/or referral to a specialist contraceptive provider, since use of the method is not usually recommended unless other more appropriate methods are not available or not acceptable
Category 4
A condition which represents an unacceptable health risk if the method is used

Reproductive tract conditions

CONDITION Cu-IUD LNG-IUS IMP DMPA POP CHC
REPRODUCTIVE TRACT CONDITIONS
Vaginal bleeding patterns
a) Irregular pattern without heavy bleeding 1 1 2 2 2 1
b) Heavy or prolonged bleeding (includes regular and irregular patterns) 2 I C 2 2 2 1
1 2
Unexplained vaginal bleeding(suspicious for serious condition) before evaluation I C I C 3 3 2 2
4 2 4
2
Cervical cancer
(a) Awaiting treatment
I C I C 2 2 1 2
4 2 4 2
b) Radical trachelectomy 3 3 2 2 1 2
Endometrial cancer
I C I C 1 1 1 1
4 2 4 2
Uterine fibroids
a) Without distortion of the uterine cavity 1 1 1 1 1 1
b) With distortion of the uterine cavity 3 3 1 1 1 1
Anatomical abnormalities
a) Distorted uterine cavity 3 3
b) Other abnormalities 2 2
Pelvic inflammatory disease
a) Past PID (assuming no current risk factor for STIs) 1 1 1 1 1 1
b) Current PID I C I C 1 1 1 1
4 2 4 2
Sexually transmitted infections (STIs)
a) Chlamydial infection (current) I C I C
i) Symptomatic 4 2 4 2 1 1 1 1
ii) Asymptomatic 3 2 3
2 1 1 1 1
b) Purulent cervicitis or gonorrhoea (current) 4 2 4 2 1 1 1 1
  • Please refer to the full guideline for recommendations on:
    • endometriosis
    • benign ovarian tumours (including cysts)
    • severe dysmenorrhoea
    • gestational trophoblastic disease
    • cervical ectropion
    • cervical intraepithelial neoplasia
    • ovarian cancer
    • other current STIs (excluding HIV and hepatitis)
    • current vaginitis (including Trichomonas vaginalis and bacterial vaginosis)
    • increased risk for STIs
I=initiation: starting a method by a woman with a specific medical condition. C=continuation: continuing with the method already being used by a woman who develops a new medical condition. Cu-IUD=copper-bearing intrauterine device; LNG-IUS=levonorgestrel-releasing intrauterine system; IMP=progestogen-onlyimplant; DMPA=progestogen-only injectable; POP=progestogen-only pill; CHC=combined hormonal contraception; PID=pelvic inflammatory disease.

UKMEC DEFINITION OF CATEGORY
Category 1 A condition for which there is no restriction for the use of the method
Category 2
A condition where the advantages of using the method generally outweigh the theoretical or proven risks
Category 3
A condition where the theoretical or proven risks usually outweigh the advantages of using the method. The provision of a method requires expert clinical judgement and/or referral to a specialist contraceptive provider, since use of the method is not usually recommended unless other more appropriate methods are not available or not acceptable
Category 4
A condition which represents an unacceptable health risk if the method is used

Breast conditions

CONDITION Cu-IUD LNG-IUS IMP DMPA POP CHC
BREAST CONDITIONS
(a) Undiagnosed mass/breast symptoms 1 2 2 2 2 I C
3 2
(b) Benign breast conditions 1 1 1 1 1 1
(c) Family history of breast cancer 1 1 1 1 1 1
(d) Carriers of known gene mutations associated with breast cancer (e.g. BRCA1/BRCA2) 1 2 2 2 2 3
(e) Breast cancer
(i) Current breast cancer 1 4 4 4 4 4
(ii) Past breast cancer 1 3 3 3 3 3
I=initiation: starting a method by a woman with a specific medical condition. C=continuation: continuing with the method already being used by a woman who develops a new medical condition. Cu-IUD=copper-bearing intrauterine device; LNG-IUS=levonorgestrel-releasing intrauterine system; IMP=progestogen-only implant; DMPA=progestogen-only injectable; POP=progestogen-only pill; CHC=combined hormonal contraception.

UKMEC DEFINITION OF CATEGORY
Category 1 A condition for which there is no restriction for the use of the method
Category 2
A condition where the advantages of using the method generally outweigh the theoretical or proven risks
Category 3
A condition where the theoretical or proven risks usually outweigh the advantages of using the method. The provision of a method requires expert clinical judgement and/or referral to a specialist contraceptive provider, since use of the method is not usually recommended unless other more appropriate methods are not available or not acceptable
Category 4
A condition which represents an unacceptable health risk if the method is used

Infection

CONDITION Cu-IUD LNG-IUS IMP DMPA POP CHC
INFECTION
HIV Infection
(a) High risk of HIV infection 2 2 1 1 1 1
(b) HIV infected
(i) CD4 count ≥200 cells/mm3 2 2 1 1 1 1
(ii) CD4 count <200 cells/mm3 I C I C 1 1 1 1
3 2 3 2
(c) Taking antiretroviral drugs Certain ARV drugs have the potential to affect the bioavailability of steroid hormones in hormonal contraception. For up-to-date information on the potential drug interactions between hormonal contraception and ARV drugs, please refer to theonline HIV drugs interaction checker. (www.hiv-druginteractions.org)
OTHER INFECTIONS
Tuberculosis
(a) Non-pelvic 1 1 1 1 1 1
(b) Pelvic I C I C 1 1 1 1
4 3 4 3
I=initiation: starting a method by a woman with a specific medical condition. C=continuation: continuing with the method already being used by a woman who develops a new medical condition. Cu-IUD=copper-bearing intrauterine device; LNG-IUS=levonorgestrel-releasing intrauterine system; IMP=progestogen-only implant; DMPA=progestogen-only injectable; POP=progestogen-only pill; CHC=combined hormonal contraception; ARV=antiretroviral.

UKMEC DEFINITION OF CATEGORY
Category 1 A condition for which there is no restriction for the use of the method
Category 2
A condition where the advantages of using the method generally outweigh the theoretical or proven risks
Category 3
A condition where the theoretical or proven risks usually outweigh the advantages of using the method. The provision of a method requires expert clinical judgement and/or referral to a specialist contraceptive provider, since use of the method is not usually recommended unless other more appropriate methods are not available or not acceptable
Category 4
A condition which represents an unacceptable health risk if the method is used

Endocrine conditions

CONDITION Cu-IUD LNG-IUS IMP DMPA POP CHC
ENDOCRINE CONDITIONS
Diabetes
(a) History of gestational disease 1 1 1 1 1 1
(b) Non-vascular disease
(i) Non-insulin dependent 1 2 2 2 2 2
(i) Insulin dependent 1 2 2 2 2 2
(c) Nephropathy/ retinopathy/ neuropathy 1 2 2 2 2 3
(d) Other vascular disease 1 2 2 2 2 3
Please refer to the full guideline for recommendations on thyroid disorders
Cu-IUD=copper-bearing intrauterine device; LNG-IUS=levonorgestrel-releasing intrauterine system; IMP=progestogen-only implant; DMPA=progestogen-only injectable; POP=progestogen-only pill; CHC=combined hormonal contraception.

UKMEC DEFINITION OF CATEGORY
Category 1 A condition for which there is no restriction for the use of the method
Category 2
A condition where the advantages of using the method generally outweigh the theoretical or proven risks
Category 3
A condition where the theoretical or proven risks usually outweigh the advantages of using the method. The provision of a method requires expert clinical judgement and/or referral to a specialist contraceptive provider, since use of the method is not usually recommended unless other more appropriate methods are not available or not acceptable
Category 4
A condition which represents an unacceptable health risk if the method is used

Gastrointestinal conditions

CONDITION Cu-IUD LNG-IUS IMP DMPA POP CHC
GASTROINTESTINAL CONDITIONS
Gall bladder disease
a) Symptomatic
i) Treated by cholecystectomy 1 2 2 2 2 2
ii) Medically treated 1 2 2 2 2 3
iii) current
1 2 2 2 2 3
b) Asymptomatic 1 2 2 2 2 2
History of cholestasis
a) Pregnancy related 1 1 1 1 1 2
b) Past COC related 1 2 2 2 2 3
Viral hepatitis
a) Acute or flare 1 1 1 1 1 I C
3 2
b) Carrier 1 1 1 1 1 1
c) Chronic 1 1 1 1 1 1
Cirrhosis
a) Mild (compensated without complications) 1 1 1 1 1 1
b) Severe (decompensated) 1 3 3 3 3 4
Please refer to the full guideline for recommendations on liver tumours and inflammatory bowel disease
I=initiation: starting a method by a woman with a specific medical condition. C=continuation: continuing with the method already being used by a woman who develops a new medical condition. Cu-IUD=copper-bearing intrauterine device; LNG-IUS=levonorgestrel-releasing intrauterine system; IMP=progestogen-only implant;DMPA=progestogen-only injectable; POP=progestogen-only pill; CHC=combined hormonal contraception.

UKMEC DEFINITION OF CATEGORY
Category 1 A condition for which there is no restriction for the use of the method
Category 2
A condition where the advantages of using the method generally outweigh the theoretical or proven risks
Category 3
A condition where the theoretical or proven risks usually outweigh the advantages of using the method. The provision of a method requires expert clinical judgement and/or referral to a specialist contraceptive provider, since use of the method is not usually recommended unless other more appropriate methods are not available or not acceptable
Category 4
A condition which represents an unacceptable health risk if the method is used

Anaemias


ANAEMIAS
Please refer to the full guideline for recommendations on thalassaemia, sickle cell disease, and iron deficiency anaemia

Rheumatic diseases

RHEUMATIC DISEASES
Rheumatoid arthritis 1 2 2 2 2 2
Systemic lupus erythematosus (SLE)
(a) No antiphospholipid antibodies 1 2 2 2 2 2
(b) Positive antiphospholipid antibodies 1 2 2 2 2 4
Positive antiphospholipid antibodies 1 2 2 2 2 4

UKMEC DEFINITION OF CATEGORY
Category 1 A condition for which there is no restriction for the use of the method
Category 2
A condition where the advantages of using the method generally outweigh the theoretical or proven risks
Category 3
A condition where the theoretical or proven risks usually outweigh the advantages of using the method. The provision of a method requires expert clinical judgement and/or referral to a specialist contraceptive provider, since use of the method is not usually recommended unless other more appropriate methods are not available or not acceptable
Category 4
A condition which represents an unacceptable health risk if the method is used

Drug interactions

DRUG INTERACTIONS
Taking medication Please refer to the full guideline on drug interactions with hormonal contraception

References

full guideline available from…
Faculty of Sexual & Reproductive Healthcare 
www.fsrh.org/standards-and-guidance/external/ukmec-2016-digital-version/

UK medical eligibility criteria for contraceptive use. UKMEC 2016. May 2016


People who read this also read....

Hypertension in adults: diagnosis and management
National Institute for Health and Care Excellence
Tinnitus guidance for GPs
British Tinnitus Association
Consensus guideline for the management of common bacterial skin infections in primary care
Working Party — Gray, Ali, Dawood, Robertson, Strauss & Walton



Share or Comment on this Article
Add to Favourite Add to favourite
Please login to rate this article, view others comments or make your own.